pmid,title,journal,year,drug,disease
40546725,JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study.,Blood neoplasia,2025,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
38650754,"PD-1 Blockade-Induced Hemophagocytic Lymphohistiocytosis, a Dilemma Therapeutic Outcome in 2 Patients with CAEBV: A Case Series.",Infection and drug resistance,2024,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
35344583,A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis.,Blood,2022,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
34552486,"Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study.",Frontiers in pharmacology,2021,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
34349069,[The road to treating chronic active Epstein-Barr viral infection].,[Rinsho ketsueki] The Japanese journal of clinical hematology,2021,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
32362967,Reactivation of Epstein-Barr Virus Hepatitis in T/Natural Killer (NK) Cells Mimicking Liver T/NK-Cell Lymphoma.,Gastroenterology research,2020,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
30830248,Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein-Barr virus.,Annals of hematology,2019,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
30123428,STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target.,Oncotarget,2018,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
29270166,Disseminated Tuberculosis and Chronic Mucocutaneous Candidiasis in a Patient with a Gain-of-Function Mutation in Signal Transduction and Activator of Transcription 1.,Frontiers in immunology,2017,Ruxolitinib,Chronic Active Epstein-Barr Virus Infection
